Temozolomide and the Stupp protocol — the concurrent temozolomide (TMZ) chemoradiation followed by adjuvant TMZ chemotherapy representing the standard of care for newly diagnosed GBM since the landmark 2005 Stupp NEJM trial — creates the foundational treatment market, with the US Glioma Diagnosis Treatment Market reflecting standard chemoradiation as the commercial and clinical treatment backbone.

The Stupp trial demonstrating median survival improvement from twelve-point-one months (radiation alone) to fourteen-point-six months (TMZ + radiation) with eighteen-month survival twenty-six percent versus ten percent represented the first meaningful survival improvement in GBM in decades. Although the benefit appears modest in absolute terms, the reproducibility and manageable toxicity profile have maintained TMZ as the universal standard.

MGMT promoter methylation — the DNA repair enzyme methylation status that predicts TMZ benefit (methylated MGMT patients deriving greater benefit from TMZ) — has created the most clinically and commercially important predictive biomarker in GBM treatment. MGMT methylation testing (IHC, pyrosequencing, or methylation-specific PCR) now universally performed at GBM diagnosis, with methylated patients receiving more aggressive TMZ approaches and unmethylated patients being prioritized for novel therapy enrollment.

Bevacizumab (Avastin) — the anti-VEGF monoclonal antibody approved for recurrent GBM based on response rate improvement — despite failing to improve overall survival in newly diagnosed GBM trials (RTOG 0825, AVAglio) remains used in specific recurrent GBM clinical scenarios. The commercial reality of bevacizumab maintaining clinical use despite negative OS trials reflecting physician and patient desire for treatment options in recurrent GBM.

Do you think MGMT methylation status should determine whether newly diagnosed GBM patients receive TMZ-based treatment at all, or should all patients receive standard Stupp protocol regardless of methylation status?

FAQ

What is the Stupp protocol for glioblastoma treatment? Stupp protocol (NEJM 2005): sixty Gy radiation over six weeks concurrent with daily TMZ (75 mg/m²); four-week break; adjuvant TMZ (150-200 mg/m²) days 1-5 of twenty-eight-day cycles for six cycles; standard of care for fit newly diagnosed GBM; median overall survival approximately fourteen to sixteen months.

What is MGMT methylation and why does it predict temozolomide response? MGMT (O6-methylguanine-DNA methyltransferase) repairs TMZ-induced DNA damage; methylation silences MGMT allowing TMZ DNA damage to persist causing tumor cell death; approximately forty to fifty percent of GBM patients have methylated MGMT; methylated patients achieve approximately twenty to twenty-six months median OS versus twelve to fourteen months unmethylated.

#USGlioma #Glioblastoma Treatment #Temozolomide #StuppProtocol #MGMTmethylation #GBMchemotherapy